Page 8 - Morphosys News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Today - Breaking & Trending Today

EQS-Adhoc: Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction - adhoc - Börsennachrichten

EQSAdhoc MorphoSys AG Key word Study results Ad hoc MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Po ....

United States , Julia Neugebauer , Drug Administration , Distribution Services , Dynamic International Prognostic Scoring System , European Medicines Agency , Exchange Commission , Constellation Pharmaceuticals Inc , Lymphoma Society , Morphosy Phase , Spleen Volume Reduction , Strong Positive Trend , Symptom Reduction , Spleen Volume , Meaningful Improvements , Ruxolitinib Combination Was , New Drug Application , Marketing Authorization Application , Fast Track , Morphosy Annual Report , Regulatory Announcements , Corporate News ,

MorphoSys AG (NASDAQ:MOR) Q3 2023 Earnings Call Transcript

MorphoSys AG (NASDAQ:MOR) Q3 2023 Earnings Call Transcript November 16, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Third Quarter Statement 2023 of MorphoSys. Throughout today’s recorded call, all participants will be in a listen-only mode. The presentation will be followed by a question-and-answer session. [Operator […] ....

Jean Paul Kress , Derek Archila , Tim Demuth , Lucinda Crabtree , Wells Fargo , Biggest Car Rental Companies , Myelodysplastic Syndrome , Paul Kress , November Dividend Stocks , Car Rental Companies , Sean Paul , Julia Neugebauer , Tim Demuth , Perator Instructions , Development Plans , Lucy Crabtree ,

MorphoSys AG (NASDAQ:MOR) Receives $12.09 Average PT from Brokerages

Shares of MorphoSys AG (NASDAQ:MOR – Get Free Report) have earned an average rating of “Hold” from the nine brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the […] ....

United States , Exchange Traded Concepts , Morgan Stanley , Goldman Sachs Group , Virtu Financial , Deutsche Bank Aktiengesellschaft , Blackrock Inc , Morphosys Company Profile , Get Free Report , Marketbeat Ratings , Get Free , Morphosys Daily , Nasdaq Mor ,

EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023 - adhoc - Börsennachrichten

EQSAdhoc MorphoSys AG Key word Change in Forecast Ad hoc MorphoSys AG Reports Preliminary Q3 2023 Monjuvi US Sales and Gross Margin and Updates Financial Guidance for 2023 25Oct2023 1048 CETCEST Disc ....

United States , Julia Neugebauer , Distribution Services , Exchange Commission , Gross Margin , Updates Financial Guidance , Product Sales , Preliminary Gross Margin , Morphosy Annual Report , Regulatory Announcements , Corporate News ,

Institutional investors have a lot riding on MorphoSys AG (ETR:MOR) with 49% ownership

Key Insights Significantly high institutional ownership implies MorphoSys' stock price is sensitive to their trading. ....

Company Ownership , T Rowe Price Group Inc , Rowe Price Group , Private Companies , Institutional Ownership , Institutional Investors , Nsider Ownership , Morphosys Ag , Stock Price ,